<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="298">
  <stage>Registered</stage>
  <submitdate>26/08/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <actrnumber>ACTRN12605000365662</actrnumber>
  <trial_identification>
    <studytitle>The roles of essential oils in the modulation of immune function: Pilot study</studytitle>
    <scientifictitle>A pilot study to evaluate the potential roles for the topical application of aromatherapy essential oils in the modulation of immune function in healthy individuals</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Immune function</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants undertook a 4-week period of topical use of an aromatherapy oil mix, followed by a 2 week post-treatment period.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Complete blood count including leucocyte count and differential</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Lymphocyte subset phenotype</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Natural killer cell activity</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Erythrocyte sedimentation rate (ESR)</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>C-Reactive protein</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>High sensitivity assay (hsCRP)</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ex-vivo changes in lymphocyte activation</outcome>
      <timepoint>Measured on days 0, 14, 28 and 42</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In vivo alterations in lymphocyte cytokine production profile</outcome>
      <timepoint>Measured on Day 0, Day 14, Day 28 and Day 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In vivo alterations in liver function tests</outcome>
      <timepoint>Measured on Day 0, Day 14, Day 28 and Day 42.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In vivo alterations in urea, creatinine and electrolytes</outcome>
      <timepoint>Measured on Day 0, Day 14, Day 28 and Day 42.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Willing to comply with study protocols. The smokers must consume 10 cigarettes per day, and have done so for at least a year. The non-smokers must have never smoked.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Factors resulting in exclusion include: any significant medical problem or chronic illness, including the findings on assessment of:o BMI &gt;30 or &lt;18, o undiagnosed hypertension oro pulse irregularities consistent with pathological cardiac dysrhythmia such as atrial fibrillationHistory of allergies to fragrances, current or recent dermatitis, regular use of medications, vitamin or supplement consumption, alcohol intake of more than 7 standard drinks per week or greater than 4 on heaviest day, high levels of exercise (extreme strenuous exercise for over 60 mins &gt;twice per week)  Recreational drug use, any acute illness or infection in the preceding 2 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>5/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Sharon Kepper Aromatherapy: Fragrantia Investments</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sharon Kepper Aromatherapy</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aromatherapy essential oils were applied topically over a 28 day period to determine their efficacy in modulating immune alterations, including those associated with smoking; and to determine if they form a safe and well-tolerated treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross university Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Queensland Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joan O'Connor</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203649</phone>
      <fax>+61 2 66203307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Stephen Myers</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203403</phone>
      <fax>+61 2 66203307</fax>
      <email>smyers@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>